High‐throughput screening in natural product drug discovery in Australia utilising Australia's biodiversity
暂无分享,去创建一个
[1] H. Kawagishi,et al. Structures of Sideroxylonals from Eucalyptus sideroxylon , 1992 .
[2] F. Kathawala. HMG-CoA reductase inhibitors: an exciting development in the treatment of hyperlipoproteinemia. , 1991, Medicinal research reviews.
[3] J. Lowe,et al. A potent nonpeptide antagonist of the substance P (NK1) receptor. , 1991, Science.
[4] J M Liesch,et al. A potent nonpeptide cholecystokinin antagonist selective for peripheral tissues isolated from Aspergillus alliaceus. , 1985, Science.
[5] Y. Tsujita,et al. ML-236A, ML-236B, and ML-236C, new inhibitors of cholesterogenesis produced by Penicillium citrinium. , 1976, The Journal of antibiotics.
[6] Y. Shu,et al. Recent natural products based drug development: a pharmaceutical industry perspective. , 1998, Journal of natural products.
[7] D. Collen,et al. Thrombolytic therapy in the eighties. , 1986, Blood.
[8] A. Nishida,et al. (3R)-N-(1-(tert-butylcarbonylmethyl)-2,3-dihydro-2-oxo-5-(2-pyridyl)-1H-1,4-benzodiazepin-3-yl)-N'-(3-(methylamino)phenyl)urea (YF476): a potent and orally active gastrin/CCK-B antagonist. , 1997, Journal of medicinal chemistry.
[9] H. Haruyama,et al. Structure elucidation of the bioactive metabolites of ML-236B (mevastatin) isolated from dog urine. , 1986, Chemical & pharmaceutical bulletin.
[10] S. Dawson,et al. The status of PAI-1 as a risk factor for arterial and thrombotic disease: a review. , 1992, Atherosclerosis.
[11] R Monaghan,et al. Mevinolin: a highly potent competitive inhibitor of hydroxymethylglutaryl-coenzyme A reductase and a cholesterol-lowering agent. , 1980, Proceedings of the National Academy of Sciences of the United States of America.
[12] B. Alving,et al. Plasminogen Activator Inhibitor Type 1: Biochemistry and Evidence for Modulation of Fibrinolysis In Vivo , 1992, Seminars in thrombosis and hemostasis.
[13] B. Groombridge. Global biodiversity: status of the earth's living resources. , 1992 .
[14] D. Dickson. British ruling supports legal challenge to broad patents , 1996, Nature.
[15] S. Nakanishi,et al. Different binding epitopes on the NK1 receptor for substance P and a non-peptide antagonist , 1993, Nature.
[16] W. F. Hoffman,et al. 3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors. 4. Side chain ester derivatives of mevinolin. , 1986, Journal of medicinal chemistry.
[17] B. E. Evans,et al. Design of potent, orally effective, nonpeptidal antagonists of the peptide hormone cholecystokinin. , 1986, Proceedings of the National Academy of Sciences of the United States of America.
[18] R. Chang,et al. Biochemical and pharmacological characterization of an extremely potent and selective nonpeptide cholecystokinin antagonist. , 1986, Proceedings of the National Academy of Sciences of the United States of America.
[19] T. Kenakin,et al. Physiological effects of inverse agonists in transgenic mice with myocardial overexpression of the β2-adrenoceptor , 1995, Nature.
[20] D J Newman,et al. Natural products in drug discovery and development. , 1997, Journal of natural products.